TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01660100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein antrum isolation (PVAI)
Description: In this group, only standard PVAI will be performed during the primary procedure. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum remains isolated will enter follow-up; however, patients who have pulmonary vein-left atrium reconnection will undergo an re-isolation. Patients who have pulmonary vein antrum re-isolation are subject to a 3rd procedure 3 months later to check the status of pulmonary vein-left atrium connection. Patients will enter follow-up for long-term outcome only after permanent PVAI is confirmed by a repeat procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVAI plus left atrial posterior wall (LAPW) isolation
Description: In this group, PVAI will be extended to the entire LAPW to achieve LAPW isolation during the primary ablation. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum and LAPW remain isolated will enter follow-up; however, patients who have pulmonary vein antrum and/or LAPW reconnection will undergo a re-isolation. Patients who have pulmonary vein antrum and/or LAPW re-isolation are subject to a 3rd procedure three month later to check the presence of pulmonary vein antrum and/or LAPW re-connection. Patients will enter follow-up for long-term outcome only after PVAI and LAPW isolation are proven by a repeat procedure.
Study: NCT01675128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 183750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT03563417

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percuteneous Coronary Intervention
Description: PCI of Chronic Total Occlusions

Intervention type: OTHER
Group type: OTHER
Intervention: Optimal Medical Therapy
Description: Initiation and titration of optimal medical therapy in the control arm.
Study: NCT00199927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvastatin
Description: Starting dose of Fluvastatin of 40 mg/day uptitrated to 80 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Description: standard therapy
Study: NCT01677975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FNA (fine needle aspiration)
Study: NCT04432051

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: mechanical ventilator settings and position
Description: Mechanical ventilation settings and patient position will be re-evaluated

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilator settings and position
Description: Mechanical ventilation settings and patient position will be re-evaluated
Study: NCT00985842

Intervention type: DEVICE
Group type: OTHER
Intervention: Pe-Lite and sleeve suspension socket
Description: Prosthetic socket worn by the amputee that has a Pe-lite foam liner between the socket and the residual limb. It is suspended from the residual limb using a sleeve at the top of the socket.

Intervention type: DEVICE
Group type: OTHER
Intervention: Total Surface bearing a socket with a sleeve suspension but without suction
Description: Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a sleeve at the top of the socket.

Intervention type: DEVICE
Group type: OTHER
Intervention: Total surface bearing suction socket with a pin lock suspension
Description: Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a pin that protrudes from the bottom of the liner into the socket that is then locked in place by the amputee.

Intervention type: DEVICE
Group type: OTHER
Intervention: Total surface bearing suction socket with a sleeve suspension
Description: Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket using vacuum suction plus a sleeve at the top of the prosthetic socket to enhance the security of the suspension.

Intervention type: DEVICE
Group type: OTHER
Intervention: Vacuum-assisted socket system (Harmony System, Otto Bock)
Description: Prosthetic socket worn by the amputee where the a vacuum pump, in this case a mechanically-activated pump, creates a vacuum between the socket and the limb. This vacuum suspends the prosthetic limb from the amputee's residual limb.
Study: NCT03506919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems
Study: NCT01181024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)
Study: NCT00213278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulphate injection
Description: Vinblastine dose: 6 mg/m\^2 (10 mg max.) route intravenous administration once a week over a period of 10 weeks. If response at week 10 is greater than or equal to stable, weekly Vinblastine will be continued for 42 weeks.
Study: NCT01738997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilation 10 sec

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilation 2 min
Study: NCT03187548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casein Phosphopeptide-Amorphous Calcium Phosphate Dental Paste
Description: Application of CPP-ACP on one premolar once every 2 weeks for 3 months.
Study: NCT02309892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DOS47
Description: A treatment cycle will be 21 days, with patients receiving L-DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.
Study: NCT02289144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: 750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.
Study: NCT01027065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT107+GenHevac+entecavir or tenofovir
Description: 4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT107+ entecavir or tenofovir
Description: 4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
Study: NCT04581291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Aerobic Exercises
Description: Participants in the exercise group performed a two weeks aerobic exercise program. The exercise program consisted of walking/running on a treadmill or bicycling on a stationary bicycle. Each session is composed of five-minute warm-up slow walking or bicycling. Then the main intervention which composed of thirty-minutes of moderate-intensity aerobic exercises (walking/running or bicycling). Lastly, a five-minute of cool-down exercises (walking/running or bicycling). The exercise intensity was 60-75% of the predicted MHR (calculated as MHR=210-age).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Aerobic Exercises
Description: Participants in the exercise group performed a two weeks aerobic exercise program. The exercise program consisted of walking/running on a treadmill or bicycling on a stationary bicycle. Each session is composed of five-minute warm-up slow walking or bicycling. Then the main intervention which composed of thirty-minutes of moderate-intensity aerobic exercises (walking/running or bicycling). Lastly, a five-minute of cool-down exercises (walking/running or bicycling). The exercise intensity was 60-75% of the predicted MHR (calculated as MHR=210-age).
Study: NCT00352794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral 10 mg daily/days 1-21 of 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
Study: NCT02602028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine
Description: to compare once daily dosage schema of colchicine and twice daily dosage schema of colchicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine
Description: to compare once daily dosage schema of colchicine and twice daily dosage schema of colchicine
Study: NCT04723979

Intervention type: DRUG
Intervention: Eptacog alfa
Description: Recombinant coagulation factor VII activated
Study: NCT01497899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TDF
Description: 150/150/200/300 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TAF Placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF Placebo
Description: Tablet administered orally once daily
Study: NCT04868513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnant women to whom applied silane fluoride
Description: Pregnant women who received 0.1% silane fluoride applied as varnish in the teeth.
Study: NCT04475172

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Self-Adhesive Flowable Composite
Description: Fusio Self-Adhesive Flowable Composite combines the benefits of adhesive and restorative technology into one product . Immediately upon application Fusio conditions, bonds, and seals without the need for an etchant or an adhesive.~It is based on the bonding technology that uses glycerophosphate dimethacrylate(GPDM)to etch enamel and dentin, and hydroxyethyl methacrylate (HEMA) to enhance wetting and penetration by resin into dentin.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Self-Adhesive Flowable Composite
Description: Fusio Self-Adhesive Flowable Composite combines the benefits of adhesive and restorative technology into one product . Immediately upon application Fusio conditions, bonds, and seals without the need for an etchant or an adhesive.~It is based on the bonding technology that uses glycerophosphate dimethacrylate(GPDM)to etch enamel and dentin, and hydroxyethyl methacrylate (HEMA) to enhance wetting and penetration by resin into dentin.
Study: NCT01866514

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: proximal humerus intraosseous vascular access
Description: The arm receiving the IO needle is positioned with the arm abducted to shoulder level (in position required for surgery), with the arm rotated inward, into the optimal position, with the palms faced down. Deeply palpate the humerus until the junction of the humeral shaft and the humeral head, the surgical neck is identified; the insertion site is in the surgical neck. With the 45mm IO needle placed perpendicular to the plane of the skin, the IO needle is inserted into the surgical neck using a slightly superior angle of insertion and the needle is inserted to the hub. The stylet will be removed and an EZ-Connect primed with 2% preservative-free lidocaine will be attached to the catheter hub. Aspirate return will be attempted to confirm needle placement within the medullary cavity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% preservative-free lidocaine
Study: NCT04868513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnant women to whom applied silane fluoride + 1% chlorhexidine
Description: Pregnant women who received silane fluoride + 1% chlorhexidine applied as varnish in the teeth.
Study: NCT02275559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Course (HLC)
Description: The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
Study: NCT03191604

Intervention type: OTHER
Intervention: Video intervention
Description: Video clips of endoscopy footage with just HD-WLE and clips with NBI will be shown to endoscopists.
Study: NCT00863135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: continuous positive airways pressure

Intervention type: DEVICE
Group type: OTHER
Intervention: Control
Description: Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time
Study: NCT02804386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection
Study: NCT02612168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Melanoma Image Analysis Algorithm (MIAA)
Description: The images will be analysed by MIAA (Melanoma Image Analysis Algorithm). The MIAA result for PLs that are biopsied will be compared to the diagnosis made from the biopsy. The MIAA result for PLs not biopsied will be compared to clinician diagnosis.
Study: NCT00569855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine
Description: 0.125 to 1 mg/kg given i.v. over 15 to 45 minutes in preparation for cardiopulmonary bypass; may be continued at 0.125 mg/kg/day in ICU
Study: NCT02925104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Study: NCT00852722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat study diet
Description: The low fat study diet is a very low-saturated-fat, plant food based diet. It will be approximately 10% fat, 14% protein and 76% carbohydrate.The diet is is starched based and also contains fresh or frozen fruits and vegetables and there is no animal meat used, including no use of fish. This diet is very low in saturated fats and enriched in unsaturated fats. Subjects do not take dietary supplements.
Study: NCT01128543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib and Vinorelbine
Description: Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib and Vinorelbine
Description: Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
Study: NCT02609438

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short breaks
Description: Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take a 1-minute active break every 30 minutes during the workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Long breaks
Description: Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take two 15-minute activity breaks during each workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
Study: NCT04723979

Intervention type: OTHER
Intervention: Standard of care
Description: Patients have been treated according to local routine clinical practice at the discretion of the treating physician.
Study: NCT01866514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZ-IO
Study: NCT02493673

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure device
Description: (ResMed Spirit S8)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous positive airway pressure device
Description: (ResMed Spirit S8)
Study: NCT03410355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BMAC/PRP Injection
Description: Patients will be placed on an office procedure under local anesthesia. The investigators will harvest 60 cm3 of bone marrow from posterior iliac crest and centrifuged obtaining approximately 3 cm3 of autologous bone marrow-mesenchymal stem cells concentrate. At the same time, 60cm3 of peripheral blood will be taken and centrifugated once, to obtain approximately 3 cm3 of PRP. After activation of platelet rich plasma cells they will be mixed in one syringe with the concentrated BMaC and both will be injected in the hip joint under ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone Injection
Description: An intraarticular injection of 1cm3 with 80mg of methylprednisolone combined with 3cm3 of 0.25% bupivacaine will be injected in the hip joint under ultrasound.
Study: NCT03590613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772
Description: GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772
Description: GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route
Study: NCT00994240

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrodessication & Curettage
Description: Electrodessication \& Curettage 1 or 3 cycles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrodessication & Curettage
Description: Electrodessication \& Curettage 1 or 3 cycles
Study: NCT03902912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
Study: NCT02968303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib and Cobimetinib
Description: Combination of Vemurafenib with Cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with Nivolumab and Ipilimumab
Study: NCT01843764

Intervention type: DEVICE
Intervention: HRP2 and LDH based rapid diagnostic tests for P.falciparum
Study: NCT02404285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Next Science Acne Gel
Description: Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
Study: NCT01438918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SD-6010
Description: 200 mg tablets once a day for 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SD-6010
Description: 50 mg tablets once a day for 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once a day for 2 years
Study: NCT03541265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: long-acting Bupivacaine extended release liposome compound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: long-acting Bupivacaine extended release liposome compound
Study: NCT05654285

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cola beverage with sucrose and stevia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cola beverage with sucrose and stevia